2004
Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study
Nelson JC, Mazure CM, Jatlow PI, Bowers MB, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biological Psychiatry 2004, 55: 296-300. PMID: 14744472, DOI: 10.1016/j.biopsych.2003.08.007.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic Uptake InhibitorsAdultAntidepressive Agents, Second-GenerationAntidepressive Agents, TricyclicChromatography, High Pressure LiquidDepressive DisorderDesipramineDouble-Blind MethodDrug Therapy, CombinationFemaleFluoxetineHumansMaleMiddle AgedNorepinephrinePsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsSerotoninTreatment OutcomeConceptsMontgomery-Asberg Depression Rating ScaleHamilton Depression Rating Scale scoresDepression Rating Scale scoresNonpsychotic unipolar major depressionPatient withdrew consentTreatment-resistant patientsWeeks of hospitalizationWeeks of treatmentCombination of fluoxetineOnset of actionAdequate plasma levelsDouble-blind conditionsDepression Rating ScaleTreatment of depressionRating Scale scoresUnipolar major depressionDrug plasma concentrationsDMI doseWithdrew consentAntidepressant medicationRandomized studyReuptake inhibitionSerotonergic agentsPlasma levelsMajor depression
1998
Acute Neuroleptic Treatment in Elderly Patients Without Dementia
Mazure C, Nelson J, Jatlow P, Bowers M. Acute Neuroleptic Treatment in Elderly Patients Without Dementia. American Journal Of Geriatric Psychiatry 1998, 6: 221-229. PMID: 9659955, DOI: 10.1097/00019442-199800630-00005.Peer-Reviewed Original ResearchConceptsNon-elderly adultsElderly patientsNeuroleptic treatmentAcute responseLow dosesLow-dose neuroleptic treatmentAcute neuroleptic treatmentAdverse effectsHigh-dose treatmentLow-dose treatmentDrug blood levelsPrimary psychotic illnessInitial doseBlood levelsPsychotic illnessEffective treatmentPatientsDose ratioLonger durationTreatmentLower ratesDosesAdultsResponseNeuroleptics
1991
Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis
Mazure C, Nelson J, Jatlow P, Bowers M. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biological Psychiatry 1991, 30: 475-482. PMID: 1932395, DOI: 10.1016/0006-3223(91)90309-a.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdultBipolar DisorderChromatography, High Pressure LiquidDepressive DisorderDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHomovanillic AcidHumansMaleMethoxyhydroxyphenylglycolMiddle AgedPerphenazinePrognosisProspective StudiesPsychiatric Status Rating ScalesPsychotic DisordersSchizophreniaSchizophrenic PsychologyConceptsPlasma homovanillic acidHomovanillic acidFree homovanillic acidClinical responseEarly clinical responsePlasma-free homovanillic acidUseful clinical predictorClinical predictorsNeuroleptic treatmentAcute psychosisDopamine metabolismNoradrenergic functioningMethoxyhydroxyphenylglycolFavorable responsePsychotic inpatientsGood responseSignificant decline